RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Comapny Performed, Management disappointed. Michael, OMG! Did either of you actually listen to the call? The question Prakash Gowd had was: How MANY of the 60 drugs are new drugs or just reformulations of existing drugs? He was asking, I quote "on a proportion basis." It was a relatively simple question. Borkowski could have responded 50 drugs, 30 drugs, 25 drugs, 10 drugs, 5 drugs, 1 drug, 0 drugs etc. Simple question that required a simple answer that in no way gave any competitor any advantage or disadvantage either way so I am not sure where you are going with the silence is smart argument. These pharma analysts do not get excited about reformulations and the analyst was trying to determine how many of the 60 were going to be reformulations versus how many were going to be NEW chemicals that investors could actually get excited about. Borkowski fluffed his response back to Prakash, and every analyst on the call knows it. It left the investment community with the impression that these must be all reformulations and there is nothing in the way of new drugs in the pipeline And indeed the share price showed that there is nothing to be excited about. God Bless You!
{quote=MichaelSilvia1]I think he is saying that in the pharmaceutical industry, a company shouldn't reveal too many specifics on the conference call. If they are releasing x drug for y disease in May, and competitors know this, then competitors will step up promotion in April to release the same drug. In this industry, there is a lot of lobbying physicians and promotion.
Comparing this to another industry is foolish. Apple has many patents, and brand recognition. Pharmaceuticals have many drugs for the same purpose, and the drugs that are prescribed may depend on lobbying, promotion, and timing.
But you don't care about this, because you are shorting. WHY DOESN'T CONCORDIA GENERATE AD REVENUE LIKE FACEBOOK?! THIS IS UNACCEPTABLE. THIS IS GOING TO $10.[/quote]